Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration

Detalles Bibliográficos
Autores principales: Ference, Brian A, Cannon, Christopher P, Landmesser, Ulf, Lüscher, Thomas F, Catapano, Alberico L, Ray, Kausik K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6047439/
https://www.ncbi.nlm.nih.gov/pubmed/29020411
http://dx.doi.org/10.1093/eurheartj/ehx450
_version_ 1783339943501758464
author Ference, Brian A
Cannon, Christopher P
Landmesser, Ulf
Lüscher, Thomas F
Catapano, Alberico L
Ray, Kausik K
author_facet Ference, Brian A
Cannon, Christopher P
Landmesser, Ulf
Lüscher, Thomas F
Catapano, Alberico L
Ray, Kausik K
author_sort Ference, Brian A
collection PubMed
description
format Online
Article
Text
id pubmed-6047439
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-60474392018-07-19 Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration Ference, Brian A Cannon, Christopher P Landmesser, Ulf Lüscher, Thomas F Catapano, Alberico L Ray, Kausik K Eur Heart J Current Opinion Oxford University Press 2018-07-14 2017-08-14 /pmc/articles/PMC6047439/ /pubmed/29020411 http://dx.doi.org/10.1093/eurheartj/ehx450 Text en © The Author 2017. Published by Oxford University Press on behalf of the European Society of Cardiology http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Current Opinion
Ference, Brian A
Cannon, Christopher P
Landmesser, Ulf
Lüscher, Thomas F
Catapano, Alberico L
Ray, Kausik K
Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration
title Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration
title_full Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration
title_fullStr Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration
title_full_unstemmed Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration
title_short Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration
title_sort reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (pcsk9) inhibitors and statins: an analysis of fourier, spire, and the cholesterol treatment trialists collaboration
topic Current Opinion
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6047439/
https://www.ncbi.nlm.nih.gov/pubmed/29020411
http://dx.doi.org/10.1093/eurheartj/ehx450
work_keys_str_mv AT ferencebriana reductionoflowdensitylipoproteincholesterolandcardiovasculareventswithproproteinconvertasesubtilisinkexintype9pcsk9inhibitorsandstatinsananalysisoffourierspireandthecholesteroltreatmenttrialistscollaboration
AT cannonchristopherp reductionoflowdensitylipoproteincholesterolandcardiovasculareventswithproproteinconvertasesubtilisinkexintype9pcsk9inhibitorsandstatinsananalysisoffourierspireandthecholesteroltreatmenttrialistscollaboration
AT landmesserulf reductionoflowdensitylipoproteincholesterolandcardiovasculareventswithproproteinconvertasesubtilisinkexintype9pcsk9inhibitorsandstatinsananalysisoffourierspireandthecholesteroltreatmenttrialistscollaboration
AT luscherthomasf reductionoflowdensitylipoproteincholesterolandcardiovasculareventswithproproteinconvertasesubtilisinkexintype9pcsk9inhibitorsandstatinsananalysisoffourierspireandthecholesteroltreatmenttrialistscollaboration
AT catapanoalbericol reductionoflowdensitylipoproteincholesterolandcardiovasculareventswithproproteinconvertasesubtilisinkexintype9pcsk9inhibitorsandstatinsananalysisoffourierspireandthecholesteroltreatmenttrialistscollaboration
AT raykausikk reductionoflowdensitylipoproteincholesterolandcardiovasculareventswithproproteinconvertasesubtilisinkexintype9pcsk9inhibitorsandstatinsananalysisoffourierspireandthecholesteroltreatmenttrialistscollaboration